Abstract

Background and Aims: IP-10 molecule is a new biomarker to predict response to treatment in chronic HCV infection. Also urine IP-10 has been suggested as a biomarker in other infections. But already, it has low data in urine as well as serum level of IP-10 for HCV infection. The aim of this study was to assess urine and serum level of IP-10 in patients with type 1 and 3a HCV infection.

Materials and Methods: In this case-control study, 105 patients with HCV infection were involved in three 35 people groups. Blood and urine sample of all patients was collected to determine IP-10 level. Finally, data analysis was reported using SPSS, mean statistics analysis and T test.

Results: The age mean was 41.6±11.2 ranging 21-68. Urine and serum level of IP-10 in patient group was significantly higher than control (p=0.001). Serum level of IP-10 based on HCV genotype was higher significantly in genotype 1a than 3a (p=0.001) but there was no significant difference of urine IP-10 level between genotypes 1a and 3a.

Conclusions: The results show IP-10 is a proper marker to determine the prognosis of fibrosis and progress liver inflammation and on the other hand, the prediction of response to treatment differs in various genotypes of HCV infection.